Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $722.9 million.

  • Ligand Pharmaceuticals' Non-Current Assets rose 1198.71% to $722.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 1004.54%. This contributed to the annual value of $610.2 million for FY2024, which is 1099.12% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Non-Current Assets stood at $722.9 million, which was up 1198.71% from $595.7 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Non-Current Assets' 5-year high stood at $857.7 million during Q1 2021, with a 5-year trough of $481.4 million in Q2 2023.
  • Its 5-year average for Non-Current Assets is $666.7 million, with a median of $610.2 million in 2024.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 14147.44% in 2021, then plummeted by 4217.52% in 2023.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Non-Current Assets stood at $832.8 million in 2021, then plummeted by 40.08% to $499.1 million in 2022, then grew by 10.16% to $549.8 million in 2023, then increased by 10.99% to $610.2 million in 2024, then increased by 18.46% to $722.9 million in 2025.
  • Its Non-Current Assets was $722.9 million in Q3 2025, compared to $595.7 million in Q2 2025 and $596.1 million in Q1 2025.